Herpes zoster vaccine (HZV): utilization and coverage 2009 – 2013, Alberta, Canada

Liu, Xianfang C.; Simmonds, Kimberley; Russell, Margaret L.; Svenson, Lawrence W.

doi:10.1186/1471-2458-14-1098

Cited by 23 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, uptake in the USA was initially very low, though has shown improvement in recent years; claims data from over 6 million US adults aged 60 years and above, suggest zoster vaccine coverage increased from 1.3% in 2007 to 19.5% by 2013 [88]. Coverage in Canada, where the vaccine is not publicly funded, has been similarly low; in the region of Alberta in Canada, 8.4% of patients age 60 years and over were vaccinated between 2009 and 2013 [89]. Both patient and provider barriers, such as high vaccine cost, complex methods of reimbursement and the requirement for freezer storage, have been suggested to explain the poor uptake of zoster vaccine in the USA [90,91].…”

Section: Development Of a Vaccine Against Zoster Efficacy And Safetymentioning

confidence: 99%

Varicella and herpes zoster vaccine development: lessons learned

Warren‐Gash

Forbes

Breuer

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Before vaccination, varicella zoster virus (VZV), which is endemic worldwide, led to almost universal infection. This neurotropic virus persists lifelong by establishing latency in sensory ganglia, where its reactivation is controlled by VZV-specific T-cell immunity. Lifetime risk of VZV reactivation (zoster) is around 30%. Vaccine development was galvanised by the economic and societal burden of VZV, including debilitating zoster complications that largely affect older individuals. Areas covered: We describe the story of development, licensing and implementation of live attenuated vaccines against varicella and zoster. We consider the complex backdrop of VZV virology, pathogenesis and immune responses in the absence of suitable animal models and examine the changing epidemiology of VZV disease. We review the vaccines’ efficacy, safety, effectiveness and coverage using evidence from trials, observational studies from large routine health datasets and clinical post-marketing surveillance studies and outline newer developments in subunit and inactivated vaccines. Expert commentary: Safe and effective, varicella and zoster vaccines have already made major inroads into reducing the burden of VZV disease globally. As these live vaccines have the potential to reactivate and cause clinical disease, developing alternatives that do not establish latency is an attractive prospect but will require better understanding of latency mechanisms.

show abstract

Section: Development Of a Vaccine Against Zoster Efficacy And Safetymentioning

confidence: 99%

Varicella and herpes zoster vaccine development: lessons learned

Warren‐Gash

Forbes

Breuer

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…As described elsewhere [6], each individual is assigned a personal health number that acts as a unique lifetime identifier (ULI). The ULI is recorded each time a person accesses the healthcare system and this allows for deterministic linkage across multiple administrative data sets held by the Alberta Ministry of Health (Alberta Health).…”

Section: Data Sources and Data Extractionmentioning

confidence: 99%

“…Immunization data for publicly and privately funded qHPV and bHPV vaccines as well as demographic data for immunized individuals from Imm/ ARI and PIN were extracted, for the period September [6], postal codes were used to classify persons as rural vs. urban residents and to assign income quintiles which were estimated from 2011 Canadian census data for Alberta.…”

Section: Data Sources and Data Extractionmentioning

confidence: 99%

HPV Vaccine utilization, Alberta 2008/09 – 2013/14 School year

et al. 2015

View full text Add to dashboard Cite

Background: In Canada both bivalent (bHPV) vaccine and quadrivalent HPV vaccine (qHPV) are authorized for use. In Alberta, while both vaccines are available for private purchase, only qHPV is publicly funded for school girls in grades 5 and 9 as of 2013. We describe HPV vaccine uptake in Alberta, by school year, from the start of the publicly funded program in the Fall of 2008 through to August 31 st 2014 and estimate the cumulative proportion of the female population who were vaccinated by the end of the 2013/14 school year. Methods: We used data from the Alberta Ministry of Health Immunization and Adverse Reaction to Immunization repository (publicly funded vaccine), the population-based Pharmaceutical Information Network information systems (privately purchased vaccine) for the period September 1, 2008 to August 31, 2014 and demographic data from the Alberta Health Care Insurance Plan Registry. We estimate vaccine uptake rates and explore them by attributes of person, time, place, vaccine funding, and number of doses received. We estimated the cumulative proportions of the female population (by age group and number of doses received) who had received HPV vaccine by the end of the 2013/14 school year. Results: Of the 169,259 unique individuals who received one or more doses of HPV vaccine over the period, 98.3 % were females, and 83.8 % received publicly funded vaccines. Vaccine uptake increased over the period. The cumulative proportion of females aged 9-26 years as of 2013/14 who had received two or more doses of vaccine was 34.3 %; for those aged 10-11 years 59.6 % and for those aged 14-15 years, 76.0 %. For those aged 9-26 years, 31.3 % had received three doses of vaccine. Conclusion: HPV vaccine uptake rates have increased in Alberta over the study period, most prominently among the age groups targeted by the publicly funded school-girl vaccine program.

show abstract

“…Kanada'da bu oranın 2013 yılında %8.4 olduğu tahmin edilmektedir (18). Avrupa'da ve Türkiye'de ise bu konuda yapılmış çalışma bulunmamaktadır.…”

Section: Introductionunclassified

Awareness and Attitude of Family Physicians About Human Papilloma Virus and Herpes Zoster Vaccines

Revanli¹,

Yuceer²,

Şenol³

et al. 2016

Klimik Dergisi

View full text Add to dashboard Cite

Objective: In this study, it is aimed to examine knowledge and attitudes about HPV and herpes zoster vaccines among family physicians. Methods: The study was conducted at 5th Annual International Family Practice Congress (19-23 Decembe, 2014, Antalya, Turkey) using face-to-face survey forms handed out to 263 family physicians. Statistical data has been analyzed using STATA 9.0 program. Results: Majority of the participants (89.3%) had knowledge about HPV vaccine and 156 (59.5%) of them had been recommending the HPV vaccine to their patients. The main reason of not prescribing (50.3%) was expensiveness. It is observed that recommending the vaccine is correlated with having knowledge about the vaccine (p<0.001). The physicians who have knowledge about HPV vaccine (p=0.006) and are older than 40 years of age (p=0.016) are more likely to prescribe HPV vaccine. The number of participants with some knowledge about herpes zoster vaccine was 157 (59.7%) and 161 (65.7%) of the participants were in favor of recommending the vaccine. According to multivariate analysis, recommending herpes zoster vaccine correlates with having knowledge about the vaccine (p=0.043), being woman (p=0.03), being older than 40 years (p=0.007) and having had shingles or having a relative who have had shingles (p=0.006). 3)'ü HPV aşısı hakkında bilgi sahibidir ve bunların 156 (%59.5)'sı HPV aşısını hastalarına önermektedir. HPV aşısının reçete edilmemesinin en büyük nedeni (%50.3) pahalı olmasıdır. Aşı hakkında bilgi sahibi olunmasının hastalara HPV aşısının önerilmesiyle ilişkili olduğu bulunmuştur (p<0.001). HPV aşısı hakkında bilgi sahibi olanların (p=0.006) ve 40 yaşın üzerindeki hekimlerin (p=0.016) daha sık HPV aşısı reçete ettiği saptanmıştır. Anket formu uygulanan katılımcıların 157 (%59.7)'si zona aşısı hakkında bilgi sahibidir ve 161 (%65.7)'i hastalarına zona aşısı önermeye olumlu bakmaktadır. Çok değişkenli analize göre aşı hakkında bilgi sahibi olma (p=0.043), kadın olma (p=0.03), 40 yaşın üzerinde olma (p=0.007), kendisinin veya bir yakınının zona geçirmiş olması (p=0.006) hekimlerin hastalarına zona aşısı önermesiyle ilişkili bulunmuştur. Sonuçlar: HPV ve zona aşılarını önermede ve HPV aşısını reçete etmede temel belirleyici aile hekimlerinin bu konulardaki bilgi düzeyleridir. HPV ve zona aşılarının indikasyonlu hastalara önerilmesi için, aile hekimlerinin bu konuda bilgilendirilmesi gerekmektedir. Klimik Dergisi 2016; 29(1): 15-20. Anahtar Sözcükler: HPV, HPV aşısı, zona, zona aşısı, aile hekimleri.

show abstract

Herpes zoster vaccine (HZV): utilization and coverage 2009 – 2013, Alberta, Canada

Cited by 23 publications

References 19 publications

Varicella and herpes zoster vaccine development: lessons learned

Varicella and herpes zoster vaccine development: lessons learned

HPV Vaccine utilization, Alberta 2008/09 – 2013/14 School year

Awareness and Attitude of Family Physicians About Human Papilloma Virus and Herpes Zoster Vaccines

Contact Info

Product

Resources

About